Method for assessing the risk of peptic ulcer, comprising the steps of determining quantitatively the concentrations of pepsinogen I (PGI) and gastrin-17 in a serum sample
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Mar 29, 2005
Grant Date -
N/A
app pub date -
Jan 16, 2002
filing date -
Apr 30, 1999
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The present invention concerns a method for assessing the risk of peptic ulcer by determining the presence and topographic phenotype of gastritis in an individual, by determining quantitatively the pepsinogen I and gastin-17 concentrations in a serum sample from the said individual, selecting a method-specific reference value and cut-off value for respective analyte, assessing the topography and phenotype of gastritis based on a comparison of the pepsinogen I and gastrin-17 concentrations so determined with their respective method-specific reference and cut-off values, and correlating the so assessed gastritis phenotype with the risk for peptic ulcer. Preferably also Helicobacter antibodies are determined in the sample.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully